AC Immune Analyst Ratings
AC Immune Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 455.56% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 08/07/2023 | 455.56% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 06/28/2023 | 455.56% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 05/01/2023 | 455.56% | HC Wainwright & Co. | → $16 | Reiterates | → Buy |
| 04/19/2023 | 455.56% | HC Wainwright & Co. | → $16 | Reiterates | → Buy |
| 03/17/2023 | 455.56% | HC Wainwright & Co. | → $16 | Reiterates | → Buy |
| 07/11/2022 | 247.22% | SVB Leerink | $15 → $10 | Maintains | Outperform |
| 12/20/2021 | 420.83% | SVB Leerink | $17 → $15 | Maintains | Outperform |
| 03/24/2021 | 455.56% | HC Wainwright & Co. | $11 → $16 | Maintains | Buy |
| 12/10/2019 | 281.94% | HC Wainwright & Co. | $8 → $11 | Reiterates | → Buy |
| 02/01/2019 | — | UBS | Downgrades | Buy → Neutral | |
| 11/13/2018 | 525% | Leerink Swann | → $18 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/13/2023 | 455.56% | HC Wainwright & Co. | → 16 美元 | 重申 | 購買 → 購買 |
| 08/07/2023 | 455.56% | HC Wainwright & Co. | → 16 美元 | 重申 | 購買 → 購買 |
| 06/28/2023 | 455.56% | HC Wainwright & Co. | → 16 美元 | 重申 | 購買 → 購買 |
| 05/01/2023 | 455.56% | HC Wainwright & Co. | → 16 美元 | 重申 | → 購買 |
| 04/19/2023 | 455.56% | HC Wainwright & Co. | → 16 美元 | 重申 | → 購買 |
| 03/17/2023 | 455.56% | HC Wainwright & Co. | → 16 美元 | 重申 | → 購買 |
| 2022 年 11 月 7 日 | 247.22% | SVB Leerink | 15 美元 → 10 美元 | 維護 | 跑贏大盤 |
| 2021 年 12 月 20 日 | 420.83% | SVB Leerink | 17 美元 → 15 美元 | 維護 | 跑贏大盤 |
| 2021 年 3 月 24 日 | 455.56% | HC Wainwright & Co. | 11 美元 → 16 美元 | 維護 | 買 |
| 2019 年 10 月 12 日 | 281.94% | HC Wainwright & Co. | 8 美元 → 11 美元 | 重申 | → 購買 |
| 02/01/2019 | — | 瑞銀（UBS） | 降級 | 買入 → 中性 | |
| 11/13/2018 | 525% | Leerink Swann | → 18 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for AC Immune (ACIU)?
AC Immune（ACIU）的目標價格是多少？
The latest price target for AC Immune (NASDAQ: ACIU) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $16.00 expecting ACIU to rise to within 12 months (a possible 455.56% upside). 6 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月13日公佈了AC Immune（納斯達克股票代碼：ACIU）的最新目標股價。該分析公司將目標股價定爲16.00美元，預計ACIU將在12個月內升至12個月內（可能上漲455.56％）。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for AC Immune (ACIU)?
分析師對AC Immune（ACIU）的最新評級是多少？
The latest analyst rating for AC Immune (NASDAQ: ACIU) was provided by HC Wainwright & Co., and AC Immune reiterated their buy rating.
HC Wainwright & Co. 提供了AC Immune（納斯達克股票代碼：ACIU）的最新分析師評級，AC Immune重申了其買入評級。
When is the next analyst rating going to be posted or updated for AC Immune (ACIU)?
下一次分析師對AC Immune（ACIU）的評級將在何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AC Immune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AC Immune was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與AC Immune的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。AC Immune 的最新評級是在 2023 年 11 月 13 日公佈的，因此您應該預計，下一個評級將在 2024 年 11 月 13 日左右公佈。
Is the Analyst Rating AC Immune (ACIU) correct?
分析師評級 AC Immune (ACIU) 是否正確？
While ratings are subjective and will change, the latest AC Immune (ACIU) rating was a reiterated with a price target of $0.00 to $16.00. The current price AC Immune (ACIU) is trading at is $2.88, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的AC Immune（ACIU）評級得到了重申，目標股價爲0.00美元至16.00美元。AC Immune（ACIU）目前的交易價格爲2.88美元，在分析師的預測區間內。